Table 1.
Clinical and Demographic Characteristics of Patients With Malignant Lymphoma.
| Characteristics | Total n = 31 |
Non-Sarcopenia n = 20 (65%) |
Sarcopenia n = 11 (35%) |
P-value |
|---|---|---|---|---|
| Age, years | 76.0 ± 5.6 | 75.9 ± 4.5 | 76.1 ± 7.4 | .90 |
| Height, cm | 156.1 ± 8.9 | 159.9 ± 8.5 | 151.2 ± 7.7 | <.05 |
| Body weight, kg | 54.0 ± 15.9 | 60.6 ± 9.6 | 44.4 ± 6.2 | <.05 |
| BMI, kg/m2 | 22.1 ± 5.6 | 23.5 ± 6.4 | 19.4 ± 2.2 | <.05 |
| Sex | ||||
| Male | 14 (45.0) | 12 (60.0%) | 2 (18.0%) | <.05 |
| Female | 17 (55.0) | 8 (40.0%) | 9 (82.0%) | |
| Performance status | ||||
| 0 | 22 (71.0) | 17 (85.0%) | 5 (45.4%) | .06 |
| 1 | 5 (16.0) | 2 (10.0%) | 3 (27.3%) | |
| 2 | 4 (13.0) | 1 (5.0%) | 3 (27.3%) | |
| Non-Hodgkin Lymphoma Type | ||||
| DLBCL | 29 (93.6) | 19 (95.0%) | 10 (91.0%) | |
| FL | 1 (3.2) | 1 (5.0%) | 0 (0%) | |
| MALT | 1 (3.2) | 0 (0%) | 1 (9.0%) | |
| Chemotherapy | ||||
| R-CHOP | 26 (83.9) | 18 (90.0%) | 8 (72.7%) | |
| Number of courses | 6.5 ± 0.9 | 6.7 ± 1.0 | 6.3 ± 0.7 | |
| Other than R-CHOP | 5 (16.1) | 2 (10.0%) | 3 (27.3%) | |
| Number of courses | 5.8 ± 0.4 | 6.0 ± 0.0 | 5.7 ± 0.6 | |
| Treatment effect | .20 | |||
| Complete response | 23 (74.2%) | 13 (65.0%) | 10 (90.9%) | |
| Partial response | 8 (25.8%) | 7 (35.0%) | 1 (9.1%) | |
| Adherence to Exercise Therapy, % | 95.5 ± 4.3 | 95.6 ± 5.1 | 95.3 ± 2.6 | .89 |
| Length of hospitalization, days | 143.5 ± 28.7 | 143.9 ± 27.2 | 142.8 ± 33.8 | .93 |
Values are presented as means ± standard deviations (SD) or number. Statistical testing at baseline was performed using independent Student’s t-tests or Pearson’s χ2 tests. P < .05 compared with the non-sarcopenia and sarcopenia groups.
Abbreviations: BMI, body mass index; ECOG-PS, eastern cooperative oncology group performance status; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MALT, mucosa-associated lymphoid tissue. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.